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summary
It is still unknown whether there is an association between the use of certolizumab pegol (CZP) in rheumatic 
patients and the onset of cardiac arrhythmias. We describe the cases of two patients with rheumatoid arthritis 
(RA) treated with CZP as the first-line biological drug and methotrexate (MTX), who developed an arrhyth-
mic event. The first was a 60-year-old, hypertensive male smoker, the second a 66-year-old dyslipidemic 
female non-smoker. Both were diagnosed as having RA in 2010, and started treatment with MTX plus CZP. 
The first patient developed undatable atrial fibrillation, which was resistant to pharmacological treatment 
and electrical cardioversion. The second patient developed an atrial flutter, which was treated with a beta-
blocker. In both cases, we set a cautious interval between two consecutive administrations of CZP and, in the 
first case, also reduced the dose of MTX without any worsening of RA activity. Although many studies have 
shown that tumor necrosis factor (TNF)-alpha plays a pathogenetic role in inducing an arrhythmogenic sub-
strate that is apparently rescued by anti-TNF drugs, there is still a lack of conclusive data. We suggest caution 
in any patient developing a cardiac event (including rhythm disorders) during treatment with a conventional 
or biological disease-modifying anti-rheumatic drug. 
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n	 INTRODUCTION
The anti-tumour necrosis factor-alpha (anti-TNFa) agents approved for the 
treatment of rheumatoid arthritis (RA) 
and spondyloarthritis (SpA) are biologi-
cal drugs with well-characterized safety 
and efficacy profiles. Certolizumab pegol 
(CZP) is a pegylated antigen-binding frag-
ment of a humanized monoclonal antibody 
against TNFa that is licensed for use in pa-
tients with RA or SpA (1, 2). Because of its 
molecular structure, CZP rapidly reaches 
inflamed joints and provides symptomatic 
relief from the time of its first administra-
tions (3). 
TNFa plays a crucial role in remodelling 
acutely or chronically damaged heart tis-
sue. However, administering an anti-TNFa 
agent in patients with cardiac disorders 
may be simultaneously useful and detri-
mental as cases of precipitating heart fail-
ure and arrhythmias have been reported 
during treatment with infliximab, etaner-
cept and adalimumab, whose use is there-
fore contraindicated in patients with New 
York Heart Association class III and IV 
heart failure. No data have yet been pub-
lished about the risk of CZP-induced ar-
rhythmia, which is described as being an 
uncommon side effect in drug data sheets 
and pharmacovigilance reports. 
We describe two cases of cardiac arrhyth-
mias occurring during treatment with CZP 
as the first biological line in two RA pa-
tients. 
n	 CASE REPORTS
Case #1
The first patient was a 60-year-old, hyper-
tensive male smoker whose hypertension 
had been treated with an angiotensin-con-
verting enzyme inhibitor, a thiazide diuret-
ic (enalapril/hydrochlorothiazide 20/12.5 
mg/day), a calcium channel antagonist 
(lacidipine 4 mg/day) and a beta-blocker 
(bisoprolol 1.25 mg/day) from the age of 
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42 years. He began experiencing periph-
eral arthralgias in October 2010 and was 
referred to our center. At the first visit the 
patient had both wrists and knees tender 
and swollen and laboratory tests revealed 
the presence of anti-citrullinated peptide 
antibodies and rheumatoid factor. A diag-
nosis of early RA (4) was made and treat-
ment with methotrexate (MTX) 15 mg/
week associated with prednisone 5 mg/
daily was promptly prescribed, which led 
to remission lasting for nearly two years. 
However, in July 2012, the patient experi-
enced an arthritic flare [8 swollen joints, 
9 tender joints, erythrocyte sedimentation 
rate (ESR) = 22 mm 1st h, C-reactive pro-
tein (CRP) = 3.4 mg/L, disease activity 
score on 28 joints (DAS28) = 4.97] and 
due to the partial efficacy of MTX, after a 
careful screening for the use of anti-TNF 
drugs, CZP 200 mg every other week was 
added in November 2012. 
The combined treatment led to a rapid 
improvement in clinical and laboratory 
parameters, although it had less effect on 
auto-antibody titres. 
The baseline clinical examination revealed 
a bradycardic rhythm probably related to 
the use of the beta-blocker and, in October 
2013, about one year after starting CZP, 
he was admitted to the Emergency De-
partment because of an undatable episode 
of atrial fibrillation (AF) that failed to re-
spond to anti-arrhythmic treatment with 
amiodarone and flecainide. Echocardiog-
raphy revealed left atrial dilatation (48 
mm) and moderate mitral and tricuspid 
valve insufficiency. 
The patient immediately started treatment 
with an oral anti-coagulant (warfarin) and, 
after three attempts at electrical cardiover-
sion in January, February and March 2014, 
sinus rhythm was eventually restored. 
Treatment with amiodarone 100 mg/day 
was continued until April 2015, when it 
was stopped by the patient, and AF re-oc-
curred in May 2015. 
Meanwhile, given the clinical remission 
of RA and the potential risk of using an 
anti-TNF agent during a cardiac event, the 
interval between CZP injections was ex-
tended to three weeks in May 2014 (when 
the dose of MTX was lowered to 7.5 mg/
week) and then to four weeks in October of 
the same year. 
The patient is currently still arrhythmic 
(slow heart rate AF) and receiving a treat-
ment with bisoprolol 1.25 mg/day and 
apixaban 10 mg/day. His anti-hypertensive 
treatment has been maintained, and the 
continued treatment with MTX 7.5 mg/
week and CZP 200 mg every 28 days is 
still ensuring good control of the rheumatic 
disease (DAS28=1.79 in June 2015). 
Case #2
The second patient was a 66-year-old non-
smoker female, who had diet-treated dys-
lipidemia since 2001. In March 2010, she 
was diagnosed as having seropositive RA 
and treatment with MTX 15 mg/week was 
started. Concomitantly, she reported peri-
odic extra-systoles and anxiety symptoms 
that were treated with bromazepam as 
needed. Echocardiography performed in 
2010 for a suspected organic heart disease 
only revealed mitral valve prolapse. 
As RA disease activity was only par-
tially controlled (7 swollen and tender 
joints, ESR=58 mm 1st h, CRP=5.3 mg/L, 
DAS28=5.62), CZP 200 mg every other 
week was added in June 2012. This was 
fairly successful clinimetrically, although 
there was little change in her auto-antibody 
titres. In December 2013, an increase in 
liver enzyme levels led to a reduction in the 
dose of MTX (7.5 mg every 10 days) and, 
in May 2015, hydroxychloroquine 200 mg/
day was added. 
In June 2015, she attended the Emergen-
cy Department because of the onset of 
tachyarrhythmia, which proved to be an 
atrial flutter. A new echocardiography ex-
amination revealed initial left atrial dila-
tation, and treatment with an oral antico-
agulant plus heparin and a beta-blocker 
(carvedilol 3.125 mg/day) was prescribed. 
At the time of her last visit to our cen-
tre (June 2015), RA was in remission 
(DAS28=2.50); the treatment with con-
ventional disease modifying antirheu-
matic drugs (DMARDs) was maintained, 
whereas the administration of CZP was ta-
pered to one injection every 21 days. The 
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patient is currently waiting to undergo 
radio-frequency ablation of the arrhyth-
mogenic focus. 
n	 DISCUSSION
TNFa plays a crucial role in cardiac tis-
sue remodeling. The myocardiocytes of 
patients affected by heart failure express 
TNFa receptors and may also synthesize 
TNFa which induces the activation of 
nuclear factor kappa-light-chain-enhancer 
of activated B cells and favors myocar-
diocyte proliferation and apoptosis, the 
deposition of extracellular matrix, and the 
up- or down-regulation of metalloproteases 
(MMP). It also increases the amount of in-
tracytosolic calcium ions and the produc-
tion of nitric oxide (5). The systemic in-
flammation occurring during the course of 
rheumatic diseases can also affect cardiac 
tissue and generate histological changes 
that increase the risk of arrhythmias. There 
is much evidence to support the pathoge-
netic role of cytokines such as TNFa and 
interleukin (IL)-6 in AF (6-8), and sys-
temic inflammation, increased CRP levels 
and a pro-coagulant state are also risk fac-
tors for AF-related thromboembolism (9). 
In animal models, by binding to TNFRI 
and TNFRII on atrial myocardiocytes and 
fibroblasts, TNFa may increase the deposi-
tion of extracellular matrix, reduce the ex-
pression of connexin-40, and increase the 
release of MMP, thus finally contributing 
to atrial remodeling (10). 
The use of anti-TNFa agents can be use-
ful in reducing the inflammatory burden 
and restoring endothelial function, but may 
simultaneously interfere with left ventricu-
lar remodeling or induce the complement-
dependent cytotoxicity or antibody-depen-
dent cell-mediated cytotoxicity of myo-
cardiocytes. The neutralization of TNFa 
induced by administering the monoclonal 
antibody infliximab to Trypanosoma cruzi-
infected mice restores cardiac inflamma-
tion by increasing the level of IL-10 while 
the decrease in IL-17 concentrations reduc-
es the deposition of fibronectin, and thus 
prevents the risk of arrhythmias (11). 
TNFa also seems to affect the ion-potential 
currents of myocardiocytes. Experiments 
on mice treated with TNFa have high-
lighted a reduced intake of sarcoplasmic 
Ca2+, possibly related to the nitrosylation 
of RyR2 channels (12, 13). This reduction 
in Ca2+ levels may be responsible for de-
pressed cell contractility and the develop-
ment of aberrant sparks or hump-like de-
polarizations, which are risk factors for the 
occurrence of an arrhythmic event. Patients 
with ankylosing spondylitis or inflamma-
tory bowel diseases often have a prolonged 
QT interval (14), which, according to some 
authors, can be restored by treatment with 
infliximab (15). Neither of our patients had 
alterations of the QT interval, as emerged 
by an electrocardiographic test performed 
at baseline and after 12 month of treatment 
wit CZP. Murine models have shown that 
TNFa may promote exercise-induced atri-
al remodeling and favor the occurrence of 
AF, both of which can be prevented by the 
use of etanercept (16). Moreover, the use of 
infliximab in RA patients seems to improve 
echocardiographic findings of diastolic 
dysfunction and left atrial volumes within 
the first three months of treatment (17). 
A recent review of arrhythmic events in 
RA patients found an increased risk of sud-
den cardiac death (often related to malig-
nant ventricular arrhythmias, a prolonged 
QT interval frequently associated with in-
creased CRP levels, and AF) in comparison 
with the general population; some of these 
anomalies may be normalized by treatment 
with the biological agent tocilizumab (18). 
The higher incidence of arrhythmic events 
can be attributed to the detrimental effects 
of systemic inflammation on the myocar-
dium and the triggering of the autonomous 
sympathetic system. 
Few published reports have highlighted an 
association between the risk of developing 
cardiac arrhythmia and the concomitant 
treatment with a TNFa blocker (19-21), 
and this association seems to be stronger 
in RA patients with a prolonged QT inter-
val (22). Accordingly, trials of anti-TNF 
agents during cardiac failure or post-infarc-
tion have not led to any conclusive findings 
and were stopped prematurely (23). 
To the best of our knowledge, there are no 
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published case reports of arrhythmia dur-
ing treatment with CZP that, like other 
anti-TNF drugs, acts by blocking the re-
modeling effects of TNFa. Although the 
apoptosis of myocardiocytes is less intense 
because of the absence of crystallizable 
fragments, it can be sustained by the ac-
tivation of the pro-apoptotic pathway via 
TNFRI and TNFRII, or by means of the 
mechanism of reverse signaling, which has 
been demonstrated to be highly active dur-
ing CZP therapy. 
The safety of CZP has been tested in clini-
cal trials and pre-pivotal placebo-con-
trolled studies involving more than 4000 
RA patients, and analyses of aggregate 
data and the information arising from post-
marketing surveillance have classified the 
occurrence of arrhythmias (including AF) 
as uncommon (24). Furthermore, only 
three cases of tachycardia were reported in 
the CZP arm of the CERTAIN trial (25). 
Both of our patients had a history of altered 
sinus rhythm (extrasystoles and bradycar-
dia), and the concomitant use of MTX even 
at medium-low doses of 7.5-15 mg/week 
may have contributed to the development 
of arrhythmias, an association that is sup-
ported by some published alerting reports 
(26). Similarly, the concomitant use of hy-
droxychloroquine in patient #2 may have 
been an aggravating factor, even though 
there are only rare reports of severe heart 
conduction disorders (bundle branch block/
atrioventricular block), during treatment 
with hydroxychloroquine, with complete 
remission after its discontinuation (27). 
n	 CONCLUSIONS
Our two RA patients experienced cardiac 
arrhythmias during combined CZP and 
MTX treatment. The interference of anti-
TNF agents with the physiological pro-
cesses governing the correct function of the 
sinus node or heart conductance apparatus 
is still a matter of debate. However, given 
the number of reports of cardiac events 
developing during anti-TNF treatment, 
patients with RA and concomitant cardiac 
risk factors (e.g., extrasystoles, hyperten-
sion, or valvulopathies) should be referred 
to a cardiologist and assessed before and 
during treatment. In both cases, the devel-
opment of the arrhythmic event may be ex-
plained by a predisposing organic condition 
and/or the use of conventional and biologic 
DMARDs that may have acted as a trigger. 
Once RA remission has been achieved, con-
sideration should be given to tapering the 
dose or increasing the interval between two 
consecutive administrations of the TNFa-
blocker. Reducing the conventional DMARD 
burden may be an alternative choice. 
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